Bladder Cancer Weekly

November 04, 2024

Videos

Peer-to-Peer Clinical Conversations

36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan

Yair Lotan

Yair Lotan joins Zachary Klaassen to discuss the 36-month follow-up data of nadofaragene firadenovec for BCG-unresponsive bladder cancer.

Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka

Sarah Psutka

Zachary Klaassen speaks with Sarah Psutka about cognitive resilience in bladder cancer care.

Beyond the Abstracts

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B) - Beyond the Abstract

Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials - Beyond the Abstract

Conference Coverage

SCS AUA 2024: Does the Use of Continuous Bladder Irrigation After TURBT Increase the Risk of Complications?

SCS AUA 2024: Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

SCS AUA 2024: Bladder Cancer Recurrence Analysis in Veterans and Outcomes (BRAVO): White Light Versus Blue Light Cystoscopy Outcomes Among NMIBC Patients in an Equal Access Setting

SCS AUA 2024: Exposures and Bladder Cancer Risk Among Military Veterans: A Systemic Review and Meta-Analysis

SCS AUA 2024: High Risk NMIBC Treatment: The Case for Bladder Sparing Therapy

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials.

ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update.

Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.

Prehabilitation in patients undergoing bladder cancer surgery - A systematic review and meta-analysis.

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.

Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution

Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis.

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.

Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.

Altered immunophenotypic expression in the peripheral bladder cancer immune landscape.

Long-term oncologic outcomes and complications of robot-assisted radical cystectomy for the treatment of urothelial carcinoma of the bladder.

Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.

Efficacy and Safety of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer After Immunotherapy - Expert Commentary

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC